The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Novo Nordisk (NVO – Research Report), retaining the price target of ...

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Novo Nordisk CEO commits to exploring ways to make weight-loss drugs more affordable for U.S. patients after hearing from ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

Novo Nordisk has a price fix solution for uninsured patients with diabetes, but not for HSA holders or people with normal ...

The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish ...

We recently published a list of 10 Best Foreign Stocks To Buy Now. In this article, we are going to take a look at where Novo ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

While both Danes and the Danish government seem pleased with Novo Nordisk and the company’s enormous earnings, the large ...